Topline results from the open-label, Phase III SIMPLE trial evaluating 5-day and 10-day dosing durations of remdesivir in hospitalized patients with severe manifestations of COVID-19 disease. Gilead Sciences
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest